Skip to main content
. 2018 Apr 18;41(8):797–806. doi: 10.1007/s40264-018-0662-2

Fig. 3.

Fig. 3

Utilization of risk minimization tools among healthcare professionals (HCPs). (a) Proportion of HCPs who used the HCP-FAQ brochure when discussing the benefit–risk profile of aripiprazole with patients. (b) Proportion of HCPs (by experience) who used HCP-FAQ brochure when discussing benefit–risk profile of aripiprazole with patients/caregivers. *Data were combined for responses “yes, at all, or most, patient visits” and “yes, but mostly with new patients only”. FAQ frequently asked questions, PCIB patient/caregiver information brochure